Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2019

View Archived Issues

Secretome spills tumors' secrets

Hearing loss gene therapy works in adult mice

Dengue antibodies promote Zika-induced microcephaly

OKYO Pharma and collaborators report in vivo data for OKYO-0101 in dry eye murine model

Inflazome patents new NLRP3 inflammasome inhibitors

Boehringer Ingelheim presents promising data from proof-of-concept trial of BI-655130

AbbVie presents Mcl-1 inhibitors

Shanghai Ennova Biopharmaceutical identifies PD-1/PD-L1 interaction inhibitors

Allergan presents phase I/II results for bimatoprost sustained-release implants

Novel gene therapy prevents the onset of retinal degeneration in vivo

University of Toledo describes new HDAC inhibitors

Patient enrollment ongoing in phase II study of VRP-HER2 vaccine plus pembrolizumab

Promising interim data reported from first cohort of SUNRISE-PD study of AXO-Lenti-PD

ACADIA Pharmaceuticals divulges 5-HT2A receptor ligands

Extended evaluation phase findings from SONICS study of Recorlev in endogenous Cushing's syndrome

Characterization of novel negative allosteric modulators of metabotropic glutamate mGlu5 receptor

Steroidogenic 17beta-HSD2 inhibition for targeted intracrine therapy in bone fracture healing

Phase II results of TOL-463 for the treatment of bacterial vaginosis and vulvovaginal candidiasis

Mutations in TONSL, a fundamental DNA repair protein, cause SPONASTRIME dysplasia

Phase IIb FLUTE study of APT-1011 in eosinophilic esophagitis meets primary endpoint

Bridge Medicines signs agreement with Weill Cornell Medicine to develop novel S1P receptor modulator

CKAP4 unveiled as a new therapeutic target for PDAC

Phase III trials of vadadustat in Japanese patients with anemia due to CKD meet primary endpoint

Seres and AstraZeneca collaborate to study use of microbiome therapeutics in immuno-oncology

Axovant reports 3-month data on patient with infantile Tay-Sachs disease treated with AXO-AAV-GM2

FDA approves Dupixent for use in adolescents with moderate to severe atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...